Since IDH1-mutated tumors show a favorable patient survival and since the IDH1 status is considered to be an independent prognostic marker for WHO grade III gliomas [29], we decided to exclude IDH1-mutated samples from further analysis. This evidence concerns the gene IDH1 and central nervous system cancer.